Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/39847| Title: | Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. | Authors: | An Y.;Chen S.;Zhang X.;Su Y.;Guo J.;Shen N.;Morand E.F. ;Yu D.;Li Z.;Xu C.;Hou Z.;Leong Y.A.;Zhu L.;Feng J.;Li Y.;Jia Y.;Li C.;Liu X.;Ye H.;Ren L.;Li R.;Yao H.;He J.;Wei Y.;Sun X.;Chen Y.;Deng J.;Jin Y.;Gan Y.;Hu X.;Jia R. | Institution: | (He, Zhang, Sun, Jin, Gan, Jia, Xu, Zhu, An, Jia, Li, Liu, Ye, Ren, Li, Yao, Li, Chen, Zhang, Su, Guo, Li) Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (Wei, Hou, Feng, Yu) Laboratory of Immunology for Environment and Health, Shandong Analysis and Test Center, Shandong Academy of Sciences, Jinan, China (Chen, Hu, Leong, Yu) Laboratory for Molecular Immunomodulation, Department of Biochemistry and Molecular Biology, Infection and Immunity Program, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia (Deng, Shen, Yu) China-Australia Centre for Personalised Immunology, Shanghai Renji Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China (Morand, Yu) Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia | Issue Date: | 20-Sep-2016 | Copyright year: | 2016 | Publisher: | Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom) | Place of publication: | United Kingdom | Publication information: | Nature Medicine. 22 (9) (pp 991-993), 2016. Date of Publication: 01 Sep 2016. | Journal: | Nature Medicine | Abstract: | Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease characterized by altered balance of activity between effector and regulatory CD4+ T cells. The homeostasis of CD4+ T cell subsets is regulated by interleukin (IL)-2, and reduced production of IL-2 by T cells is observed in individuals with SLE. Here we report that treatment with low-dose recombinant human IL-2 selectively modulated the abundance of regulatory T (Treg) cells, follicular helper T (TFH) cells and IL-17-producing helper T (TH17) cells, but not TH1 or TH2 cells, accompanied by marked reductions of disease activity in patients with SLE.Copyright © 2016 Nature America, Inc. All rights reserved. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1038/nm.4148 | PubMed URL: | 27500725 [http://www.ncbi.nlm.nih.gov/pubmed/?term=27500725] | ISSN: | 1078-8956 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/39847 | Type: | Article | Subjects: | *recombinant human interleukin 2/sc [Subcutaneous Drug Administration] *recombinant human interleukin 2/dt [Drug Therapy] injection site reaction/si [Side Effect] low drug dose male mouse multiple cycle treatment nonhuman open study priority journal prospective study regulatory T lymphocyte single drug dose SLEDAI *systemic lupus erythematosus/dt [Drug Therapy] systemic lupus erythematosus/dt [Drug Therapy] *T lymphocyte subpopulation Th17 cell Th2 cell adult aged animal experiment animal model article *CD4+ T lymphocyte clinical article controlled study cytokine production drug dose reduction drug withdrawal female flu like syndrome/si [Side Effect] human infection/si [Side Effect] treatment response aldesleukin/cm [Drug Comparison] interleukin 17 prednisone *recombinant interleukin 2/ae [Adverse Drug Reaction] *recombinant interleukin 2/cm [Drug Comparison] *recombinant interleukin 2/dt [Drug Therapy] *recombinant interleukin 2/sc [Subcutaneous Drug Administration] unclassified drug *recombinant human interleukin 2/ae [Adverse Drug Reaction] *recombinant human interleukin 2/cm [Drug Comparison] flu like syndrome / side effect human infection / side effect injection site reaction / side effect low drug dose male mouse multiple cycle treatment nonhuman open study priority journal prospective study regulatory T lymphocyte single drug dose SLEDAI *systemic lupus erythematosus / *drug therapy systemic lupus erythematosus / drug therapy *T lymphocyte subpopulation Th17 cell Th2 cell animal experiment aged adult treatment response animal model Article *CD4+ T lymphocyte clinical article controlled study cytokine production drug dose reduction drug withdrawal female |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.